Sheba Pediatric CAR-T Program for Leukemia (ALL & AML) at Sheba Hospital- JCI accredited and Top-10 Hospitals 2026 by Newsweek

• 全血球計算検査
• 生化学的血液検査
• 血液内科相談
• 血液検査
• オンコヘマトロジー相談
• 白血病の包括的検査
• CAR-T細胞療法
• 栄養士による1日3食
• 24時間看護サービス
• 胸部X線
• HIV抗体検査
• B型肝炎コア抗体検査
• 抗HCV抗体検査
• 心エコー図検査
• 腫瘍専門医との診察
• 血液専門医へのコンサルテーション
• 免疫専門医への相談
• 小児血液専門医との相談
• 小児科医との相談
• 頭部MRI
• カラードプラ心エコー図検査
• 腫瘍マーカーおよび蛋白分画を含む全血球算定

• 21 日 病院で

• 空港－ホテル間送迎

Sheba Pediatric CAR-T Program for Leukemia (ALL & AML)

At Sheba Medical Center, children and young patients with leukemia have access to one of the most advanced and trusted CAR-T therapy programs in the world. The program specializes in treating acute lymphoblastic leukemia (ALL) and Acute Myeloid Leukemia (AML), including relapsed or treatment-resistant cases using highly personalized immunotherapy.

A Personalized Treatment Designed for Each Patient

CAR-T therapy uses the patient’s own immune system to recognize and destroy leukemia cells. This approach is especially important for patients who have not responded to standard treatments.

At Sheba, the entire process is performed on-site, ensuring speed and optimal quality:

Apheresis – collection of immune (T) cells
Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center
Infusion – reintroduction of modified cells to target leukemia

Because no steps are outsourced, treatment can begin quickly and is typically completed within ~10 days. CAR-T acts as a “living therapy,” continuing to work in the body over time.

Expert Care in a Supportive Environment

Patients are treated by leading hemato-oncology specialists, under the supervision of Prof. Amos Toren, within dedicated CAR-T units.

The program provides:

Specialized pediatric and young adult CAR-T care with 24/7 monitoring
A multidisciplinary team (hematology, oncology, immunology)
A supportive, patient- and family-centered environment
Full international patient services, including travel and care coordination
Proven Outcomes and Global Leadership

Sheba is a global leader in CAR-T therapy, with strong clinical outcomes:

~90% remission in pediatric patients
~80% in young adults (up to 23 years)
~70% in adults

The program is experienced in treating complex and high-risk leukemia cases, offering options when other treatments are limited.

Comprehensive Evaluation and Ongoing Support

Each patient undergoes a full diagnostic work-up, including:
advanced imaging, bone marrow biopsy, genetic and molecular testing, as well as cardiac and pulmonary evaluation.

Care is provided in English, Russian, and Arabic, ensuring clear communication and continuous support for international families.

A Place Patients and Families Can Trust

By combining advanced science, rapid access to treatment, and compassionate care, Sheba offers one of the most trusted CAR-T programs for leukemia focused on achieving remission and helping patients return to a healthy, active life.

• 専任医療コーディネーター
• 医療旅行手配 — 特別パートナー価格での航空券・ホテル予約
• 医療旅行中の患者擁護